Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xeloda pancreatic cancer survival benefit:

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche's oral fluoropyrimidine agent Xeloda (capecitabine) significantly prolongs survival in first-line pancreatic cancer when added to standard chemotherapy, the firm reports Nov. 2. Data from a 533-patient Phase III trial showed that patients receiving Xeloda in combination with gemcitabine had a 1.4 month median survival benefit compared to gemcitabine alone (7.4 months vs. 6 months; hazard ratio=0.80). The trial is one of nine Xeloda combination studies partially funded by Roche and ongoing at several National Comprehensive Cancer Network institutions. Another oral oncologic, Genentech/OSI's Tarceva (erlotinib), was approved Nov. 2 for use in pancreatic cancer (see Approvals In Brief)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel